https://www.selleckchem.com/pr....oducts/tofa-rmi14514
There have been reports of clinically relevant uterine bleeding events among women of reproductive age exposed to rivaroxaban. The aim of this study was to compare the risk of severe abnormal uterine bleeding (SAU resulting in transfusion or surgical intervention among women on rivaroxaban versus apixaban, dabigatran and warfarin. We conducted a retrospective cohort study in the FDA's Sentinel System (10/2010-09/2015) among females aged 18+ years with venous thromboembolism (VTE), or atrial flutter/fibrillation (AF) who newly in
Like
Comment
Share
